Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions... Show more
Axon Enterprise, Inc. is a global public safety technology company headquartered in Scottsdale, Arizona. The company develops and manufactures an integrated ecosystem of hardware, software, and cloud-based solutions for law enforcement, public safety agencies, enterprises, and governments. Its flagship products include TASER conducted energy weapons, Axon Body body-worn cameras, in-car camera systems, and the Axon Evidence digital evidence management platform. In recent years, Axon has expanded aggressively into artificial intelligence with products like Draft One (AI-generated police reports), Axon Assistant (voice-activated AI companion), and Axon Vision, as well as counter-drone security through its Dedrone acquisition. With approximately 96% of total revenue now derived from recurring subscription plans, a market capitalization exceeding $40 billion, and a future contracted bookings backlog of $14.3 billion, Axon occupies a dominant competitive position in the public safety technology market. Investors follow the stock closely due to its unique blend of hardware, SaaS-like recurring revenue, and exposure to high-growth AI and aerospace-defense adjacent themes.
Over the last 30 days, AXON delivered a powerful rally of approximately 24.6%, climbing from a closing price of $423.40 on June 18, 2026, to an intraday level near $527.60 as of July 20. The ascent was not linear: the stock rode a seven-day winning streak in late June and early July that added roughly 45% in cumulative gains, punctuated by a sharp spike above $665 intraday on July 7 before a partial pullback. Despite profit-taking in the second week of July—including a decline to $510.28 by July 17—AXON maintained the bulk of its gains and traded firmly above both its 50-day and 200-day moving averages.
Zooming out to the quarterly view, the stock's trajectory is even more dramatic. AXON opened April near $432 but plunged to a 52-week low of $339.01 on April 10 amid a broader software and growth-stock selloff. From that trough, the stock mounted a sustained recovery: the Q1 2026 earnings beat on May 6 acted as a critical inflection point, sending shares up 10.6% in a single session. By the end of April, AXON had clawed back to approximately $402, and the subsequent two-and-a-half months delivered nearly continuous upward momentum. Measured from mid-April levels around $404 to the July 20 reading near $528, the stock gained roughly 30.7%, underscoring a powerful reversal driven by improving sentiment and a cascade of company-specific catalysts.
The most explosive catalyst came in late June, when federal financial disclosures revealed that President Donald Trump purchased between $1 million and $5 million worth of AXON stock in February. The disclosure landed just as news emerged that U.S. Immigration and Customs Enforcement (ICE) had solicited a $220 million TASER contract, leading investors to price in significantly stronger federal demand. The stock surged double-digit percentage points within days as the market interpreted the timing as a signal of expanding government relationships.
On the analyst front, Needham & Company delivered a major vote of confidence on July 6, raising its price target from $600 to $750 while reiterating a Buy rating. The firm cited strong second- and third-quarter bookings momentum, highlighting a newly expanded contract with the Los Angeles Police Department that more than doubled annual spend to $22 million, and a surge in Dedrone counter-drone opportunities tied to FIFA World Cup security deployments. Piper Sandler followed with its own target increase to $724, and Citizens JMP reaffirmed its Market Outperform rating with a $700 target.
Fundamentally, Axon's Q1 2026 results—reported on May 6—continued to resonate throughout the period. Revenue of $807 million grew 34% year-over-year, marking the ninth consecutive quarter above 30%. AI product revenue skyrocketed over 700% from the prior year, Dedrone counter-drone revenue jumped more than 300%, and annual recurring revenue reached $1.5 billion. Management raised full-year 2026 revenue growth guidance to 30%-32%. The future contracted bookings backlog expanded 44% to $14.3 billion, providing exceptional revenue visibility.
Institutional activity reflected conviction as well. Baillie Gifford boosted its stake by nearly 1,200% in Q4 2025, Wellington Management increased its position by 327%, and Norges Bank initiated a new stake exceeding $500 million. While CEO Patrick Smith sold 10,000 shares at approximately $643.79 on July 7, the transaction was executed under a pre-arranged Rule 10b5-1 trading plan and represented a negligible 0.33% reduction in his holdings.
The quarterly story is one of recovery from an oversold trough. AXON entered April 2026 under severe pressure: the stock had fallen roughly 30% from its August 2025 peak near $885.91, driven by a broader rotation out of software and SaaS names as AI infrastructure and semiconductor stocks captured the market's attention. The selloff intensified in early April, with AXON touching $339.01 on April 10—a 52-week low—as fears of AI disruption to traditional software models weighed on the entire sector.
The inflection point arrived with Q1 2026 earnings on May 6. Axon delivered a clear counter-narrative: rather than being disrupted by AI, the company was capitalizing on it. AI-powered products such as Draft One, Axon Assistant, and Axon Vision demonstrated rapid adoption, and the Dedrone acquisition, closed roughly 18 months prior, had already generated bookings exceeding 1.5x its purchase price. The company's ability to raise full-year guidance in the face of tariff headwinds and component cost inflation reinforced confidence in the durability of its growth model. International revenue, which doubled year-over-year to represent roughly 20% of quarterly sales, added a geographic diversification story that further differentiated Axon from domestically constrained peers. By quarter's end in late June, the Trump/ICE catalyst and the Needham upgrade added rocket fuel to what was already a fundamentally supported recovery.
Tickeron's Trending AI Robots page offers a curated selection of the platform's top-performing AI-powered trading bots. While Tickeron hosts hundreds of automated trading bots covering thousands of tickers across global markets, only the most relevant and consistently high-performing strategies are featured in this section. These bots operate across a diverse range of methodologies—including swing trading, trend following, momentum strategies, and mean-reversion models—spanning various timeframes from intraday to multi-week holds. Each bot is evaluated based on verifiable performance metrics, allowing traders to assess historical returns, drawdowns, and trade frequency before committing capital. For investors seeking data-driven, algorithmic approaches to navigate volatile markets like the one AXON has experienced, exploring the Trending AI Robots section can serve as a practical starting point.
The most immediate event on the horizon is Axon's Q2 2026 earnings report, expected in early August. Consensus estimates project EPS of approximately $1.83-$1.89 on revenue near $868-$876 million. Investors will scrutinize whether the bookings momentum highlighted by Needham and other analysts materializes in reported numbers, especially in AI and Dedrone segments. Management's updated guidance for the second half of 2026 will be critical, as will commentary on tariff impacts, component costs, and free cash flow trajectory. Beyond earnings, the status of the ICE TASER contract solicitation, continued federal adoption of Axon's product ecosystem, and any further expansion of LAPD-style large municipal contracts represent key operational catalysts. On the macro side, broader sentiment toward software and growth stocks, Federal Reserve policy direction, and the relative performance of AI infrastructure versus AI application stocks could influence AXON's valuation multiple. The stock's elevated valuation—trading at a forward P/E above 70—means that any disappointment on growth or margin metrics could trigger sharp repricing.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AXON saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 14, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 39 instances where the indicator turned negative. In of the 39 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The 10-day RSI Indicator for AXON moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AXON broke above its upper Bollinger Band on June 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
AXON moved above its 50-day moving average on June 23, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in of 373 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 260 cases where AXON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.211) is normal, around the industry mean (9.886). P/E Ratio (198.181) is within average values for comparable stocks, (90.466). Projected Growth (PEG Ratio) (3.886) is also within normal values, averaging (4.000). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (13.605) is also within normal values, averaging (35.197).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical-stage biopharmaceutical company
Industry AerospaceDefense